Understanding the patient experience in follicular lymphoma (FL), relapsed/refractory FL (R/R FL), and relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)

被引：0
|
作者：
Bell, Jill A. [1 ]
Cherepanov, Dasha [1 ]
Revicki, Dennis [2 ]
Speck, Rebecca M. [2 ]
Swett, Laura [2 ]
Stumpo, Kate [1 ]
Rong, Yuanxin [1 ]
Gordon, Leo I. [3 ]
机构：
[1] Millennium Pharmaceut Inc, Cambridge, MA USA
[2] Evidera PPD, Bethesda, MD USA
[3] Northwestern Univ, Div Hematol Oncol, Feinberg Sch Med, Chicago, IL 60611 USA
来源：
QUALITY OF LIFE RESEARCH | 2019年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
B204.2
引用
收藏
页码：S67 / S68
页数：2
相关论文
共 50 条
  • [1] HUMANISTIC BURDEN IN RELAPSED OR REFRACTORY (R/ R) FOLLICULAR LYMPHOMA (FL): A SYSTEMATIC LITERATURE REVIEW (SLR)
    Forbes, C.
    Pustulka, I
    Nunez-Gonzalez, S.
    Kumar, J.
    VALUE IN HEALTH, 2023, 26 (12) : S451 - S452
  • [2] Total Cost of Care in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Gatwood, Justin
    Masaquel, Anthony
    Ross, Ryan
    Sheinson, Danny
    Hossain, Farah
    Li, Jia
    James, Cameron
    Fox, David
    BLOOD, 2022, 140 : 7906 - 7907
  • [3] Activity and safety of ibrutinib and durvalumab in patients with relapsed or refractory follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL)
    Herrera, A.
    Goy, A.
    Mehta, A.
    Ramchandren, R.
    Pagel, J.
    Svoboda, J.
    Guan, S.
    Hill, J.
    Kwei, K.
    Liu, E.
    Phillips, T.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E17 - E18
  • [4] Patient, caregiver, and physician preferences for treatment of relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
    Vukcevic, Mirko
    Yung, Mallory
    Khan, Maliha
    Schnell, Frederick Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18710 - E18710
  • [5] Patient, Caregiver, and Physician Preferences for Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
    Vukcevic, Mirko
    Yung, Mallory
    Khan, Mali
    Houpt, Bethany
    Schnell, Frederick
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S376 - S377
  • [6] Real-world early outcomes of axicabtagene ciloleucel for relapsed or refractory (R/R) follicular lymphoma (FL).
    Jacobson, Caron Alyce
    Hemmer, Michael T.
    Hu, Zhen-Huan
    Frank, Matthew Joshua
    Popplewell, Leslie
    Ahmed, Nausheen
    Lin, Yi
    Best, Timothy
    Beygi, Sara
    Miao, Harry H.
    Fu, Christine
    Sun, Fang
    Xu, Hairong
    Pasquini, Marcelo C.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Primary Clinical Response of Relmacabtagene Autoleucel in Adults with Relapsed/Refractory Follicular Lymphoma (r/r FL) in China
    Song, Yuqin
    Ying, Zhitao
    Yang, Haiyan
    Guo, Ye
    Li, Wenyu
    Zou, Dehui
    Wu, Jianqiu
    Yang, Su
    Zhang, Pian
    Ma, Meilin
    Zhou, Zisong
    Zheng, Hongxia
    Zhu, Jun
    BLOOD, 2021, 138
  • [8] Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
    Dyer, Martin J. S.
    De Vos, Sven
    Ruan, Jia
    Flowers, Christopher
    Maddocks, Kami J.
    Rule, Simon
    Hamdy, Ahmed M.
    Izumi, Raquel
    Slatter, J. Greg
    Cheung, Jean
    Frigualt, Melanie M.
    Wei, Helen
    Mourya, Sanchita
    Hunder, Naomi N. H.
    Fowler, Nathan Hale
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] Efficacy Outcomes of Treatments for Double Relapsed/Refractory Follicular Lymphoma (R/R FL): A Systematic Literature Review
    Kahl, Brad S.
    Patel, Anik R.
    Zaidi, Omer
    Snedecor, Sonya J.
    Purdum, Anna G.
    BLOOD, 2020, 136
  • [10] Odronextamab Monotherapy for the Treatment of Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL): Focus on Clinical Pharmacology and Pharmacometrics in the ELM-1 and ELM-2 Studies
    Zhu, Min
    Conrado, Daniela
    Srinivasan, Kamal
    Brouwer-Visser, Jurriaan
    Yan, Hong
    Mohamed, Hesham
    Chaudhry, Aafia
    Ambati, Srikanth
    Harnisch, Lutz
    Davis, John D.
    BLOOD, 2023, 142
12345